Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-04-10 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm (致同会计师事务所) for the 2024 annual financial report and internal control audit of the company. It details the auditor's qualifications, independence, audit fees, quality control, and risk management related to the audit engagement. The document does not contain the actual audited financial statements or substantive financial data but rather assesses the auditor's performance and compliance with regulations. The length is 3570 characters, which is relatively short and consistent with an audit report or evaluation rather than a full annual report. It is a standalone audit-related report focusing on the auditor's performance and audit process, fitting the category of Audit Report / Information (AR). FY 2024
2025-04-10 Chinese
关于2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from 科兴生物制药股份有限公司 regarding the 2024年度利润分配方案 (2024 annual profit distribution plan). It details the dividend payout per share, total cash dividends, and related financial figures. The document includes the board and supervisory committee's approval and mentions that the plan will be submitted to the 2024 annual shareholders meeting for approval. The content focuses on dividend distribution details rather than presenting a full annual report or financial statements. The document length is 2684 characters, which is relatively short and typical for a dividend announcement. Therefore, this document fits the category of Notice of Dividend Amount (DIV).
2025-04-10 Chinese
2025年度“提质增效重回报”专项行动方案
Management Reports Classification · 95% confidence The document is a detailed company communication outlining the 2025 special action plan for quality improvement and efficiency enhancement, including strategic focus areas, governance improvements, investor relations, shareholder returns, and management responsibilities. It contains specific financial data such as revenue, net profit, total assets, equity, dividend plans, share repurchase plans, and management shareholdings. The document also discusses governance rules, internal controls, and investor communication activities. It is not a simple announcement or a brief summary but a comprehensive report on company strategy, financial performance, governance, and shareholder matters for the year 2025. The presence of detailed financial figures and management discussion indicates it is a Management Report rather than an Annual Report or Interim Report, as it focuses on explaining business trends, outlook, and strategic plans rather than presenting full audited financial statements. Therefore, the document best fits the category of Management Reports (MDA).
2025-04-10 Chinese
2024年度募集资金存放及实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company 科兴生物制药股份有限公司 for the fiscal year 2024. It includes specifics on the amount raised, usage of funds, compliance with regulatory requirements, and audit opinions from an accounting firm and a sponsoring institution. The document references regulatory guidelines and includes financial figures related to fundraising and fund usage. It is not a general annual report, earnings release, or management discussion but a specialized report focused on fundraising and capital usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length (6629 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-04-10 Chinese
2024年度独立董事述职报告（唐安）
Regulatory Filings
2025-04-10 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2022年限制性股票激励计划部分限制性股票作废事项的法律意见书
Regulatory Filings
2025-04-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.